Post marketing study of sivelestat sodium hydrate for acute lung injury associated with systemic inflammatory response syndrome

Trial Profile

Post marketing study of sivelestat sodium hydrate for acute lung injury associated with systemic inflammatory response syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Sivelestat (Primary)
  • Indications Acute lung injury
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 14 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top